GO:0034190 apolipoprotein receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034190 apolipoprotein receptor binding is a molecular function defined as binding to an apolipoprotein receptor.
• Apolipoproteins such as APOE, APOB-100, and APOM interact with receptors including LDLR and LRP1 to mediate lipid transport and clearance [1,2,3].
• The receptor-binding domain of APOE has been mapped to specific residues, and monoclonal antibodies against this domain inhibit receptor binding [4,5].
• APOE isoforms (E2, E3, E4) differ in receptor-binding affinity, with APOE2 showing defective binding that can be normalized by conformational modulators [6,7].
• Mutations in APOE, such as APOE2 Sendai, are associated with lipoprotein glomerulopathy and altered receptor interactions.
• Studying this function requires tools like knockout and point-mutation cell models, surface plasmon resonance, and ligand blotting [2,7].
Description
Apolipoprotein receptor binding (GO:0034190) is a molecular function that describes the physical interaction between an apolipoprotein and its cognate receptor. Apolipoproteins are amphipathic proteins that stabilize lipoprotein particles and direct their metabolism by serving as ligands for cell-surface receptors [1,2]. This binding event is central to lipid homeostasis, as it triggers receptor-mediated endocytosis of lipoproteins and downstream signaling. Researchers study this function to understand how genetic variations in apolipoproteins affect receptor affinity and contribute to dyslipidemias and cardiovascular disease [3,6]. The QuickGO definition states that this term encompasses binding to an apolipoprotein receptor, and it is classified under molecular_function. Experimental evidence from the 1980s established that the receptor-binding domain of human apolipoprotein E (APOE) is a discrete structural region, and that monoclonal antibodies targeting this domain block receptor interaction [4,5]. Subsequent work showed that the APOE2 isoform, which differs by a single amino acid from APOE3, exhibits markedly reduced receptor binding, providing a molecular explanation for type III hyperlipoproteinemia. More recent studies have extended these findings to other apolipoproteins, such as apolipoprotein M (APOM), which also binds to receptors and modulates lipoprotein metabolism. Thus, GO:0034190 is a critical node linking apolipoprotein structure to receptor-mediated clearance and disease risk [3,8].
apolipoprotein receptor binding At A Glance
| GO ID | GO:0034190 |
|---|---|
| GO term | apolipoprotein receptor binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to an apolipoprotein receptor, mediating lipoprotein recognition and clearance [1,2] |
| Major ligands | APOE, APOB-100, APOM [1,2,3] |
| Major receptors | LDLR, LRP1, and other apolipoprotein receptors [3,7] |
| Disease relevance | Dyslipidemia, atherosclerosis, lipoprotein glomerulopathy [3,6,8] |
What Is GO:0034190?
In simple terms, apolipoprotein receptor binding is the act of an apolipoprotein molecule attaching to a receptor protein on the cell surface. According to the Gene Ontology, this term (GO:0034190) is a molecular function defined as binding to an apolipoprotein receptor. It does not describe the downstream signaling or transport events, but rather the initial recognition and physical contact between an apolipoprotein ligand and its receptor. This function is essential for the clearance of lipoproteins from the bloodstream and for delivering lipids to tissues [2,3].
Why Is apolipoprotein receptor binding Important in Cell Biology?
Apolipoprotein receptor binding is a fundamental molecular function that controls plasma lipid levels and tissue lipid delivery [1,2]. Defects in this binding interaction are directly linked to human diseases, including familial hypercholesterolemia, type III hyperlipoproteinemia, and lipoprotein glomerulopathy [3,6,8]. Understanding the structural determinants of this binding is essential for developing therapeutics that modulate lipoprotein clearance, such as statins and PCSK9 inhibitors. Moreover, because apolipoproteins like APOE are polymorphic, studying receptor binding helps explain inter-individual differences in cardiovascular risk and neurodegeneration.
• Regulates plasma cholesterol and triglyceride levels by mediating lipoprotein uptake [1,2].
• Mutations in APOE that impair receptor binding cause type III hyperlipoproteinemia.
• APOE isoform-specific binding to LDLR influences Alzheimer's disease risk.
• APOB-100 receptor binding is the target of lipid-lowering therapies.
• APOM binding to receptors affects HDL metabolism and atherosclerosis.
• Defective receptor binding in APOE2 Sendai leads to lipoprotein glomerulopathy.
• Monoclonal antibodies against the receptor-binding domain of APOE block binding, providing research tools.
• Conformational changes in APOE can normalize receptor binding, suggesting therapeutic strategies.
• This function is conserved across species and is studied using cell-based and biochemical assays [4,7].
• Understanding this binding helps design gene editing models for cardiovascular research.
Molecular Mechanism of apolipoprotein receptor binding
Ligand Recognition and Binding Site
In simple terms: The apolipoprotein has a specific region that fits into the receptor like a key in a lock.
The receptor-binding domain of apolipoproteins is a discrete structural region. For human APOE, the receptor-binding domain was mapped using fragment binding studies, which showed that a region around residues 140-160 is critical for binding to the LDL receptor. Monoclonal antibodies raised against this domain inhibit binding, confirming its functional importance. For APOB-100, thrombolytic fragments containing the receptor-binding domain retain binding activity, as demonstrated by lipid recombinants.
Isoform-Specific Differences
In simple terms: Different versions of the same apolipoprotein can bind more or less tightly to the receptor.
APOE exists as three common isoforms: E2, E3, and E4. APOE2 has a cysteine at position 158 instead of arginine, which dramatically reduces its binding to the LDL receptor. This defective binding is a hallmark of type III hyperlipoproteinemia. However, the binding of APOE2 can be normalized by certain conformational modulators, indicating that the binding site can be rescued. APOE4 binds with similar or slightly higher affinity than APOE3, and this difference may contribute to Alzheimer's disease risk.
Receptor Specificity and Modulation
In simple terms: Apolipoproteins can bind to different receptors, and the interaction can be influenced by other molecules.
Apolipoproteins bind to a family of receptors including the LDL receptor (LDLR) and LDL receptor-related protein 1 (LRP1). The binding affinity can be modulated by the lipid environment, as shown by studies with triglyceride-rich lipoproteins. For APOM, binding to receptors such as LRP1 is influenced by its association with HDL particles. Monoclonal antibody inhibition studies have demonstrated that the receptor-binding domain of APOE is conformationally sensitive.
Conformational Changes and Disease Mutations
In simple terms: Changes in the shape of the apolipoprotein can affect how well it binds to the receptor.
The receptor-binding activity of APOE is dependent on its conformation. APOE2 Sendai, a mutant form of APOE2, exhibits diminished LDL receptor binding and high heparin binding, and is associated with lipoprotein glomerulopathy. This suggests that mutations outside the classic receptor-binding domain can also affect binding by altering protein conformation. Normalization of APOE2 receptor binding by monoclonal antibodies or other agents highlights the dynamic nature of the binding site.
Key Genes Involved in GO:0034190 apolipoprotein receptor binding
The following genes encode apolipoproteins and receptors that directly participate in apolipoprotein receptor binding (GO:0034190).
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOE | Ligand for LDLR and LRP1; receptor-binding domain mapped [4,5] | Isoform-specific binding; Alzheimer's and dyslipidemia models [6,7] |
| APOB | Major ligand for LDLR; receptor-binding domain in APOB-100 | Target for lipid-lowering therapies; knockout models |
| APOM | Binds to receptors; modulates HDL metabolism | Emerging role in atherosclerosis and diabetes |
| LDLR | Receptor for APOE and APOB; mediates endocytosis [3,7] | Familial hypercholesterolemia; CRISPR KO models |
| LRP1 | Receptor for APOE and APOM; multifunctional [1,3] | Neurodegeneration and lipid metabolism |
| VLDLR | Receptor for APOE; mediates VLDL uptake | Triglyceride metabolism; knockout studies |
| APOC1 | Modulates APOE binding to receptors | Inhibits lipoprotein lipase; research models |
| APOC2 | Activates lipoprotein lipase; affects receptor binding | Hypertriglyceridemia models |
| APOC3 | Inhibits lipoprotein lipase and receptor binding | Cardiovascular risk; knockout models |
| APOA1 | Major HDL protein; interacts with receptors | Reverse cholesterol transport; overexpression models |
| APOA2 | Modulates HDL metabolism; receptor interactions | Knockout and transgenic models |
| APOA4 | Activates LCAT; may bind receptors | Lipid metabolism; transgenic models |
| APOA5 | Modulates VLDL triglyceride levels | Hypertriglyceridemia; knockout models |
| APOD | Lipocalin family; may interact with receptors | Neuroprotection; knockout models |
| APOH | Beta-2-glycoprotein; binds to receptors | Antiphospholipid syndrome; research models |
| APOL1 | Binds to receptors; associated with kidney disease | Kidney disease; overexpression models |
| SORL1 | Receptor for APOE; sorting protein | Alzheimer's disease; knockout models |
| LRP2 | Receptor for APOE and other ligands | Kidney and brain development |
How Is apolipoprotein receptor binding Regulated?
The binding of apolipoproteins to their receptors is regulated at multiple levels. The lipid composition of the lipoprotein particle can modulate binding affinity, as shown for triglyceride-rich lipoproteins in normo- and hypertriglyceridemia. Post-translational modifications, such as oxidation, can alter receptor recognition. Additionally, the expression levels of receptors like LDLR are regulated by intracellular cholesterol via SREBP-2, indirectly affecting apolipoprotein binding capacity. Monoclonal antibodies and conformational modulators can directly inhibit or enhance binding, demonstrating that the binding site is conformationally dynamic [5,6].
apolipoprotein receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOE | Type III hyperlipoproteinemia, Alzheimer's disease [6,7] | Point mutation (APOE2, APOE4) knock-in mice or cell lines |
| APOB | Familial hypercholesterolemia, atherosclerosis | Knockout or point mutation in APOB receptor-binding domain |
| APOM | Atherosclerosis, diabetes | Overexpression and knockout cell models |
| LDLR | Familial hypercholesterolemia | CRISPR knockout in HepG2 cells |
| APOE2 Sendai | Lipoprotein glomerulopathy | Knock-in mouse model expressing mutant APOE |
Type III Hyperlipoproteinemia
Type III hyperlipoproteinemia is characterized by defective clearance of remnant lipoproteins due to impaired binding of APOE2 to hepatic receptors. The APOE2 isoform has a cysteine at position 158, which reduces its affinity for the LDL receptor and LRP1, leading to accumulation of remnant particles. This condition is associated with premature atherosclerosis and requires accurate diagnosis for effective management.
Lipoprotein Glomerulopathy
Lipoprotein glomerulopathy is a rare kidney disease characterized by deposition of lipoprotein thrombi in glomeruli. A specific mutation in APOE, termed APOE2 Sendai, exhibits diminished LDL receptor binding and high heparin binding, contributing to glomerular injury. This highlights how altered apolipoprotein receptor binding can cause organ-specific pathology.
Alzheimer's Disease
APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease. Although the exact mechanism is not fully understood, isoform-specific binding to LDLR and other receptors may influence amyloid-beta clearance and neuronal lipid metabolism. Studies using recombinant APOE isoforms have shown differences in receptor binding affinity that may contribute to disease pathogenesis.
Atherosclerosis
Apolipoprotein receptor binding is central to the clearance of atherogenic lipoproteins [2,3]. Defects in APOB-100 binding to LDLR lead to elevated LDL cholesterol and increased risk of atherosclerosis. Similarly, APOM and APOA1 interactions with receptors affect HDL function and reverse cholesterol transport, influencing atherosclerotic plaque formation.
From apolipoprotein receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a specific APOE mutation affect receptor binding? | Point mutation knock-in cell line (e.g., APOE2, APOE4) |
| What is the effect of APOE knockout on lipoprotein clearance? | APOE knockout mouse or HepG2 knockout cells |
| Can a candidate gene regulate apolipoprotein receptor binding? | Overexpression or knockout in hepatocyte cell lines |
| How does APOM affect HDL receptor binding? | APOM overexpression and knockout cell models |
| What is the binding affinity of APOB-100 fragments? | Recombinant protein binding assays with LDLR |
| Does a disease-associated variant alter receptor specificity? | Knock-in models with tagged receptors for imaging |
How to Study the apolipoprotein receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | APOE isoform binding to LDLR |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | APOB-100 fragment binding |
| Flow cytometry | Cell surface binding and uptake | Lipoprotein uptake in knockout cells |
| Confocal microscopy | Intracellular trafficking | Receptor-mediated endocytosis |
| Ligand blotting | Binding to immobilized receptors | Identifying receptor proteins |
| Monoclonal antibody inhibition | Specificity of binding domain | Mapping APOE receptor-binding domain |
| CRISPR knockout screens | Genes regulating binding | Identifying novel modulators |
| Proteomics (AP-MS) | Protein-protein interactions | Discovering new apolipoprotein receptors |
Receptor Binding Assays
Direct binding assays, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), measure the affinity and kinetics of apolipoprotein-receptor interactions [2,7]. These methods use purified recombinant proteins or synthetic peptides corresponding to the receptor-binding domain. Monoclonal antibody inhibition assays can confirm specificity by blocking binding.
Cell-Based Uptake Studies
Cellular uptake of fluorescently labeled lipoproteins or recombinant apolipoproteins can be quantified by flow cytometry or confocal microscopy. This approach assesses functional receptor binding in a physiological context. Knockout cell lines lacking specific receptors (e.g., LDLR) are used to determine receptor specificity.
Ligand Blotting
Ligand blotting (also known as Western blotting with labeled ligands) detects apolipoprotein binding to receptors immobilized on membranes. This technique is useful for identifying receptor proteins in complex mixtures and for comparing binding affinities of different apolipoprotein isoforms.
Genetic and Proteomic Approaches
CRISPR-Cas9 knockout screens can identify genes that regulate apolipoprotein receptor binding. Proteomic methods such as affinity purification coupled with mass spectrometry (AP-MS) can uncover novel receptor partners. RNA-seq and bioinformatics analyses help interpret transcriptomic changes in response to altered binding.
How CRISPR Can Be Used to Study GO:0034190 apolipoprotein receptor binding
Knockout
CRISPR knockout of apolipoprotein genes (e.g., APOE, APOB) or receptor genes (e.g., LDLR) in cell lines such as HepG2 or HEK293 provides a clean background to study receptor binding specificity. Knockout models eliminate endogenous ligand or receptor expression, allowing precise measurement of binding interactions.
Point Mutation
Introducing disease-associated point mutations (e.g., APOE2, APOE4) via CRISPR base editing or homology-directed repair creates isogenic cell lines that differ by a single amino acid [6,7]. These models are invaluable for dissecting how specific residues affect receptor binding affinity and specificity.
Knock-in
Knock-in of tagged apolipoproteins (e.g., GFP-APOE) or tagged receptors (e.g., HA-LDLR) enables live-cell imaging and biochemical tracking of binding events. Knock-in mouse models expressing human APOE isoforms are widely used to study lipoprotein metabolism and disease.
Overexpression
Overexpression of apolipoproteins or receptors using CRISPR activation (CRISPRa) or lentiviral vectors can enhance binding signals for biochemical assays. Overexpression models are useful for producing large quantities of recombinant proteins for structural studies.
How EDITGENE Supports apolipoprotein receptor binding Research
Researchers studying apolipoprotein receptor binding-related genes often need to determine whether a candidate gene is causally involved in lipoprotein recognition, clearance, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous functional validation of genes implicated in GO:0034190.
Contact EDITGENE today to design your custom CRISPR model for apolipoprotein receptor binding research.
Frequently Asked Questions About apolipoprotein receptor binding
What is apolipoprotein receptor binding?
Apolipoprotein receptor binding (GO:0034190) is a molecular function defined as the binding of an apolipoprotein to its receptor, which mediates lipoprotein recognition and clearance.
What genes are involved in apolipoprotein receptor binding?
Key genes include APOE, APOB, APOM, LDLR, LRP1, and VLDLR, among others [1,2,3].
What is the receptor-binding domain of APOE?
The receptor-binding domain of APOE is a region around residues 140-160 that directly interacts with the LDL receptor; monoclonal antibodies against this domain block binding [4,5].
How does APOE2 affect receptor binding?
APOE2 has a cysteine at position 158 that reduces its binding to the LDL receptor, leading to type III hyperlipoproteinemia.
What diseases are associated with defective apolipoprotein receptor binding?
Diseases include type III hyperlipoproteinemia, lipoprotein glomerulopathy, atherosclerosis, and Alzheimer's disease [6,7,8].
How can I study apolipoprotein receptor binding in the lab?
Common methods include surface plasmon resonance, ligand blotting, cell-based uptake assays, and CRISPR knockout models [2,3,7].
What is the role of APOM in receptor binding?
APOM binds to receptors such as LRP1 and modulates HDL metabolism, with implications for atherosclerosis.
Can CRISPR be used to model apolipoprotein receptor binding defects?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to study how specific genetic variants affect receptor binding [3,6,7].
What is lipoprotein glomerulopathy?
Lipoprotein glomerulopathy is a kidney disease caused by mutations like APOE2 Sendai that impair LDL receptor binding and increase heparin binding.
How does APOE4 differ from APOE3 in receptor binding?
APOE4 binds to the LDL receptor with similar or slightly higher affinity than APOE3, but this difference may contribute to Alzheimer's disease risk.
Conclusion
Apolipoprotein receptor binding (GO:0034190) is a central molecular function that governs lipoprotein metabolism and is directly implicated in cardiovascular, renal, and neurodegenerative diseases [1,2,3]. Decades of research have mapped the receptor-binding domains of APOE and APOB-100, revealed isoform-specific differences, and identified disease-causing mutations [4,5,6,8]. Continued investigation using CRISPR models and advanced biochemical assays will further elucidate how this binding event can be therapeutically modulated [3,7].
References
- 1. Ren K et al.. 2015. Apolipoprotein M.. Clin Chim Acta 446:21-9 PMID: 25858547
- 2. Corsini A et al.. 1987. Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments.. J Lipid Res 28(12):1410-23 PMID: 2828500
- 3. Dergunov AD. 2004. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia.. Biochemistry (Mosc) 69(7):720-37 PMID: 15310270
- 4. Innerarity TL et al.. 1983. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.. J Biol Chem 258(20):12341-7 PMID: 6313652
- 5. Weisgraber KH et al.. 1983. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.. J Biol Chem 258(20):12348-54 PMID: 6313653
- 6. Innerarity TL et al.. 1984. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation.. J Biol Chem 259(11):7261-7 PMID: 6327714
- 7. Yamamoto T et al.. 2008. Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor.. Anal Biochem 372(2):222-6 PMID: 17923100
- 8. Hoffmann MM et al.. 2001. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.. J Am Soc Nephrol 12(3):524-530 PMID: 11181800
